Bridging Gaps in Malaysian Acne Vulgaris Guidelines: Advisory Statements on Trifarotene for Facial and Truncal Acne
Journal of Cosmetic Dermatology · 2026
DOI: 10.1111/jocd.70625 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cosmetic Dermatology, 2026. Verfasst von Azura Mohd Affandi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Kuala Lumpur, Kuala Lumpur, Ministry of Health, Malaysia. Hauptthemen laut MEDLINE: Acne Vulgaris, Retinoids, Dermatologic Agents. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Galderma.
Abstract (Originalsprache)
Background
Trifarotene, a fourth‐generation topical retinoid, offers a novel therapeutic option for facial and truncal acne. However, its role was only briefly addressed in Malaysia's 2022 Clinical Practice Guidelines (CPGs) due to its unavailability at the time. This paper aims to provide expert advisory statements on the integration of trifarotene into acne management in Malaysia, addressing evidence gaps in guideline coverage, particularly for truncal acne and acne‐induced sequelae.
Methods
A literature review was conducted to synthesize evidence on trifarotene's efficacy, safety, and clinical positioning. An advisory panel of 10 Malaysian dermatologists reviewed the evidence and provided consensus through structured surveys and discussion meetings. Three illustrative case studies were included to demonstrate the real‐world application of trifarotene.
Results
Ten advisory statements were finalized, addressing trifarotene's role in acne algorithms, patient selection, dosing strategies, combination therapy, and management of acne sequelae. Evidence supports its use for both facial and truncal acne, with additional benefits in acne‐induced hyperpigmentation and atrophic scarring. The panel recommended practical approaches to optimize tolerability and adherence, such as the CTMP (Cleanse‐Treat‐Moisturize‐Photoprotect) regimen and incremental application strategies. Real‐world cases demonstrated trifarotene's utility in diverse clinical settings.
Conclusion
These advisory statements provide clinical guidance on the use of trifarotene in Malaysia and support its integration into routine acne management. As current CPGs may remain unchanged in the near term, these recommendations aim to inform evidence‐based practice while bridging gaps in local dermatologic care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Kuala Lumpur, Kuala Lumpur, Ministry of Health, Malaysia.
- Peter Ch'ng Clinic, Kuala Lumpur, Malaysia.
- Central Dermatology, Kuala Lumpur, Malaysia.
- Mahkota Medical Centre, Melaka, Malaysia.
- Department of Dermatology, Subang Jaya Medical Centre, Subang Jaya, Malaysia.
- Gleneagles Hospital Johor, Iskandar Puteri, Malaysia.
ORCID-Profile: Azura Mohd Affandi, Peter Wee Beng Ch'ng, Evelyn Wen Yee Yap, Chin Chwen Ch'ng, Seow Hoong Foo, Kang Nien How, Zhenli Kwan, Jyh Jong Tang, Wooi Chiang Tan
Förderung
- Galderma
Zitieren
APA
Mohd Affandi, A., Ch'ng, P. W. B., Teoh, B. T. Y., Yap, E. W. Y., Ch'ng, C. C., Foo, S. H., How, K. N., Kwan, Z., Tang, J. J., Tan, W. C., Kon, K., & Poh, W. T. (2026). Bridging Gaps in Malaysian Acne Vulgaris Guidelines: Advisory Statements on Trifarotene for Facial and Truncal Acne. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70625
Vancouver
Mohd Affandi A, Ch'ng PWB, Teoh BTY, Yap EWY, Ch'ng CC, Foo SH, et al. Bridging Gaps in Malaysian Acne Vulgaris Guidelines: Advisory Statements on Trifarotene for Facial and Truncal Acne. Journal of Cosmetic Dermatology. 2026. doi:10.1111/jocd.70625
BibTeX
@article{MohdAffandi2026,
author = {Mohd Affandi, Azura and Ch'ng, Peter Wee Beng and Teoh, Benji Tze Yuen and Yap, Evelyn Wen Yee and Ch'ng, Chin Chwen and Foo, Seow Hoong and How, Kang Nien and Kwan, Zhenli and Tang, Jyh Jong and Tan, Wooi Chiang and Kon, Khen and Poh, Wei Thian},
title = {Bridging Gaps in Malaysian Acne Vulgaris Guidelines: Advisory Statements on Trifarotene for Facial and Truncal Acne},
journal = {Journal of Cosmetic Dermatology},
year = {2026},
doi = {10.1111/jocd.70625}
}
EUVIMED